What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey

Other authors

Institut Català de la Salut

[Shteinberg M] Pulmonology Institute and CF Center, Carmel Medical Center and the Technion, Israel Institute of Technology, Haifa, Israel. [Boyd J] European Lung Foundation, Sheffield, UK. [Aliberti S] Dept of Pathophysiology and Transplantation, University of Milan, and Internal Medicine Dept, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy. [Polverino E] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Thorax Institute, Institute of Biomedical Research August Pi i Sunyer, University of Barcelona, Barcelona, Spain. [Harris B, Berg T] European Lung Foundation Bronchiectasis Patient Advisory Group, Edinburgh, UK

Vall d'Hebron Barcelona Hospital Campus

Publication date

2022-03-14T13:22:51Z

2022-03-14T13:22:51Z

2021-02-15



Abstract

Experiencias de los pacientes; Enfermedad pulmonar


Experiències dels pacients; Malaltia pulmonar


Patient experiences; Lung disease


Patients' experiences of NTM pulmonary disease highlight important and unmet needs for better pharmacological treatment and education of medical staff


European Respiratory Society (EMBARC Clinical Research Collaboration)

Document Type

Article


Published version

Language

English

Publisher

European Respiratory Society

Related items

ERJ Open Research;7

https://doi.org/1183/23120541.00807-2020

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

This item appears in the following Collection(s)